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the benefits of folic acid. Only ten women received their
information from a general practitioner, midwife, or
pharmacist. At the time of these studies no education
programmes had commenced.
These results showed that awareness among pregnant
women about folic acid was unsatisfactory. Yet the majority
of women are willing to take folic acid tablets
periconceptionally. A campaign to inform the public has now
begun in the Netherlands and the medical profession should
take an active part in this. As a concluding footnote, we note
that, in the Netherlands in the spring of 1994, nearly all
pharmacists had written information about folic acid and
pregnancy available for their customers. Many pharmacists
informed oral contraceptive users by means of the following
printed text on the box of pills: "If you stop using the pill
because of the wish for a child, please ask your pharmacist
for information about the use of folic acid before you become
pregnant." 
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Gastroparesis with multiple sclerosis
SIR&mdash;Patients with multiple sclerosis (MS) often report
symptoms of bowel dysfunction, especially constipation.
However, the frequency of upper gastrointestinal tract
symptoms in MS is unknown. We describe a patient with
MS and upper gastrointestinal tract symptoms due to
gastroparesis.
A 46-year-old woman with a 14-year history of MS was
admitted for a course of intravenous methylprednisolone
(500 mg daily for 5 days) because of deteriorating mobility
due to lower-limb weakness and incoordination. She also
reported nausea and anorexia over the preceding 3-4
months, with postprandial gastro-oesophageal reflux,
vomiting on several occasions, recurrent hiccups, and weight
loss of about 10 kg. There had been no abdominal pain or
altered bowel habit. She had also experienced occasional
choking episodes when eating, more frequently with liquids
than solids, and a few episodes of nasal regurgitation over the
preceding 6 months. A mild slurring dysarthria had been
present for 10 months but there was no dysphonia. Her
general practitioner had prescribed various antiemetic
medications and ranitidine without effect. An endoscopy
prior to admission had been normal except for a positive
urease test for Helicobacter pylori. Cisapride was commenced
in a dose of 10 mg three times a day without benefit. The
patient was taking ketoprofen for osteoarthritis in the hands,
and this was ceased on admission in case it was causing
gastric irritation. Sucralfate was added during the period of
corticosteroid treatment without effect. Investigations,
including repeat endoscopy and small bowel biopsy, faecal
culture, and breath hydrogen testing were all normal. A
radionuclide gastric emptying study demonstrated a severe
delay in gastric emptying, with only 19% clearance of gastric
contents 2 h after ingestion (normal range 50-80%
clearance). The dose of cisapride was increased to 20 mg
four times a day with subsequent improvement in her
symptoms. About 6 months later, the upper gastrointestinal
symptoms resolved and cisapride was stopped.
Gastric motility is stimulated by vagal parasympathetic
efferents originating in the dorsal motor nuclei in the
medulla. On magnetic resonance imaging our patient had
areas of increased signal intensity within the medulla on T2-
weighted images. These may have involved the
parasympathetic fibres with resultant gastroparesis.
Gastroparesis complicating MS may be a more frequent
problem than previously recognised. We found only two
reported cases.1,2 It may lead to poor nutrition, weight loss,
and aspiration due to gastro-oesophageal reflux, but it is
potentially treatable. Our patient responded to cisapride,
and a previously reported case" responded to
metoclopramide. We suggest that gastroparesis be
considered as a cause of unexplained upper gastrointestinal
tract symptoms in patients with MS.
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Remission of epilepsy
SIR&mdash;Sudo and Tashiro’s letter (Sept 30, p 913) displays
misunderstanding of our paper (July 15, p 140). The
National General Practice Study of Epilepsy originally
identified 1091 patients between 1984-87, of whom 564
had definite epilepsy and 228 patients had possible or
probable epilepsy.’,’ These patients were then followed up
prospectively; no extra patients were included in the latest
report, as Sudo and Tashiro claim.
We agree that patients with epileptic seizures are not easy
to diagnose, especially in the early stages. It is therefore
important in a prospective study to ascertain patients with
possible or probable epilepsy, to avoid selection bias.
Patients with probable or possible epilepsy were analysed
both together with and separately from patients with definite
epilepsy. Indeed, the NGPSE is the first prognosis study to
address this issue.
We used both the first seizure and the index seizure as the
determining seizure for assessing prognosis, and no
differences were seen between these analyses. The index
seizure was that seizure which led to diagnosis and to
registration into the study. It would induce bias to ascertain
patients from the first seizure because this might miss
patients who do not seek medical attention at this stage, or
are undiagnosed.
Sudo and Tashiro are correct in identifying that the
NGPSE used a simple, broad classification system but this
is the standard one recommended for prognostic studies by
the International League Against Epilepsy.3
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